The neuroprotective role of erythropoietin in the management of acute ischaemic stroke: from bench to bedside
Recombinant human erythropoietin was produced soon after the discovery of the erythropoietin gene in 1985 and since then, it is used in various clinical conditions such as chronic renal failure. Moreover, experimental studies have shown that erythropoietin exerts neuroprotective action as well. Rece...
Saved in:
Published in | Acta neurologica Scandinavica Vol. 118; no. 6; pp. 362 - 366 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.12.2008
Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Recombinant human erythropoietin was produced soon after the discovery of the erythropoietin gene in 1985 and since then, it is used in various clinical conditions such as chronic renal failure. Moreover, experimental studies have shown that erythropoietin exerts neuroprotective action as well. Recently, a clinical trial yielded promising results concerning the use of erythropoietin in stroke management. In this review, we summarize the main data which suggest that recombinant human erythropoietin and its analogues may indeed have a role in stroke treatment. |
---|---|
Bibliography: | istex:051E140359F92D87C7DDE3A983C699F6B6DC9FE0 ArticleID:ANE1039 ark:/67375/WNG-RSLX5BRB-W ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Feature-3 ObjectType-Review-1 |
ISSN: | 0001-6314 1600-0404 |
DOI: | 10.1111/j.1600-0404.2008.01039.x |